George Lantz, DO
Pain Medicine · Lebanon, NHNPI 1972565422
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.4%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Pacira Therapeutics, Inc. at 54.5% of the total. Reporting peaked in 2021 at $2,521 and has fallen 98.6% since, to $35 in 2024.
Across 20 payments — averaging $233.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pacira Therapeutics, Inc.$3K
- Abbott$2K
- Nevro Corp.$164
- Avanos Medical$134
- Stimwave Technologies Incorporated$134
- Ambu Inc.$37
- plus $98 from 4 others
What the payments were for
- Consulting fees$2,50053%
- Travel & lodging$1,44631%
- Food & beverage$68415%
- Education$491%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pacira Therapeutics, Inc. | 2 | $2,549 |
| Abbott | 9 | $1,562 |
| Nevro Corp. | 2 | $164 |
| Avanos Medical | 1 | $134 |
| Stimwave Technologies Incorporated | 1 | $134 |
| Ambu Inc. | 1 | $37 |
| Pacira Pharmaceuticals Incorporated | 1 | $35 |
| Boston Scientific | 1 | $27 |
| Bioventus LLC | 1 | $21 |
| Relievant Medsystems, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,679 in reported general payments places this provider in the 70th percentile of 38 pain medicine providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pregabalin | 43 | $4,103 |
| Gabapentin | 111 | $1,229 |
| Tizanidine Hcl | 21 | $114 |
| Diazepam | 49 | $105 |
| Methylprednisolone | 16 | $97 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Lebanon
- Bert FichmanLebanon$15K
- Michael BovaLebanon$12K
- Jason DonnellyLebanon$2K
- Abdullah KandilLebanon$1K
- Stephen LordonLebanon$322
- Mary Ann SurielLebanon$278
- Jeffrey BradyLebanon$277
- Kimberly YoungrenLebanon$223
- Bruce VroomanLebanon$182
- David DentLebanon$52
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.